Assessment of the effect of portal venous embolization by MRI uging liver specificity contrast material

Assessment of the effect of portal venous embolization by MRI uging liver specificity contrast material - EOB-PVE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003079

Enrollment

Registered

2010-01-25

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatobiliary malignancy

Interventions

Injection of EOB-Primovist as the contrast material at the MRI.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria 1. Biliary malignancy, primary liver tumor, metastatic liver tumor 2. Major hepatectomy is necessary to remove the malignancy. 3. Fulfill the criteria to apply portal venous embolization. 4. Informed consent of this trial is necessary. 5. Patient is more than 20 years old.

Exclusion criteria

Exclusion criteria: Exclusion criteria 1. A patient with hypersensitivity to EOB-Primovist or Gadrinium. 2. A patient with asthma. 3. A patient with sever renal dysfunction. 4. A patient with pregnancy. 5. A woman with breast-feeding. 6. A patient with severe claustrophobia or nyctophobia.

Design outcomes

Primary

Measure	Time frame
Time intensity curve of the contrast material of embolized and non-embolized liver. The level of intensity at the hepatobiliary phase of embolized and non-embolized liver.	—

Secondary

Measure	Time frame
liver function test blood concentration of primobist pathological findings of resected specimen	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026